EW analyst estimates
Edwards Lifesciences (EW) analyst ratings, the average price target and its range, and every firm's latest call.
- 18 firms rate EW: 15 buy, 3 hold, 0 sell.
- The average price target is $109.20 from None analysts, from $100.00 to $120.00.
EW analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Nov 20, 2026 | RBC Capital | RBC Capital on Edwards Lifesciences (EW): 'Top-Tier Large Cap MedTech Growth Expected to Continue in 2027' | $115.00 |
| Nov 5, 2026 | Mizuho Securities | Edwards Lifesciences (EW) PT Raised to $120 at Mizuho | $120.00 |
| Nov 5, 2026 | Wells Fargo | Edwards Lifesciences (EW) PT Raised to $113 at Wells Fargo | $113.00 |
| Nov 5, 2026 | Truist Financial | Edwards Lifesciences (EW) PT Raised to $118 at Truist Securities | $118.00 |
| Nov 4, 2026 | Truist Financial | Truist Securities Upgrades Edwards Lifesciences (EW) to Buy | $113.00 |
| Oct 27, 2026 | Deutsche Bank | TD Cowen Reiterates Buy Rating on Edwards Lifesciences (EW) | $104.00 |
| Jul 28, 2026 | UBS | Edwards Lifesciences upgraded to Buy from Neutral at UBS | $110.00 |
| Jul 24, 2026 | Leerink Partners | Edwards Lifesciences upgraded to Outperform from Market Perform at Leerink | $101.00 |
| Jul 24, 2026 | Piper Sandler | Edwards Lifesciences price target raised to $101 from $100 at Piper Sandler | $101.00 |
| Jul 16, 2026 | Truist Financial | Edwards Lifesciences price target raised to $95 from $90 at Truist | $95.00 |
| Jul 13, 2026 | RBC Capital | Edwards Lifesciences price target raised to $110 from $100 at RBC Capital | $110.00 |
| Jul 6, 2026 | Evercore ISI | Edwards Lifesciences price target raised to $100 from $93 at Evercore ISI | $100.00 |
| Jun 30, 2026 | BTIG | Edwards Lifesciences price target raised to $110 from $100 at BTIG | $110.00 |
| Apr 27, 2026 | Barclays | Edwards Lifesciences price target raised to $110 from $104 at Barclays | $110.00 |
| Apr 24, 2026 | Truist Financial | Edwards Lifesciences price target raised to $90 from $89 at Truist | $90.00 |